FCCC LOGO Faculty Publications
Bradley SV , Smith MR , Hyun TS , Lucas PC , Li L , Antonuk D , Joshi I , Jin F , Ross TS
Aberrant huntingtin interacting protein 1 in lymphoid malignancies
Cancer Res. 2007 Sep 15;67(18) :8923-31
PMID: 17875735   
Back to previous list
Abstract
Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non-Hodgkin's and Hodgkin's lymphomas and that patients with lymphoid malignancies frequently had anti-HIP1 antibodies in their serum. Moreover, p53-deficient mice with B-cell lymphomas were 13 times more likely to have anti-HIP1 antibodies in their serum than control mice. Furthermore, transgenic overexpression of HIP1 was associated with the development of lymphoid neoplasms. The HIP1 protein was induced by activation of the nuclear factor-kappaB pathway, which is frequently activated in lymphoid malignancies. These data identify HIP1 as a new marker of lymphoid malignancies that contributes to the transformation of lymphoid cells in vivo. [Cancer Res 2007;67(18):8923-31].
Notes